Importantly, DHCR24 inhibition by SH42 decreases plasma FFA and CE levels, without increasing plasma total TAG and DAG levels (Fig 3), which implies that LXRα activation by desmosterol, in contrast to synthetic agonists, does not lead to hyperlipidemia. This evidence concerns the gene DHCR24 and hyperlipidemia.